TISIDB

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Nucleus Note=Translocates into the cytoplasm following phosphorylation by MAPKAPK2 (PubMed:14517288). Likewise, phosphorylation by PRKCD promotes translocation from the nucleus into the cytoplasm, where it is associated with free and cytoskeleton-bound polysomes (PubMed:18285462).
Domain	PF00076 RNA recognition motif. (a.k.a. RRM
Function	RNA-binding protein that binds to the 3'-UTR region of mRNAs and increases their stability (PubMed:14517288, PubMed:18285462). Involved in embryonic stem cells (ESCs) differentiation: preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), stabilizing them, promoting ESCs differentiation (By similarity). Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs (PubMed:8626503, PubMed:17632515, PubMed:18285462, PubMed:23519412). Binds avidly to the AU-rich element in FOS and IL3/interleukin-3 mRNAs. In the case of the FOS AU-rich element, binds to a core element of 27 nucleotides that contain AUUUA, AUUUUA, and AUUUUUA motifs. Binds preferentially to the 5'-UUUU[AG]UUU-3' motif in vitro (PubMed:8626503). With ZNF385A, binds the 3'-UTR of p53/TP53 mRNA to control their nuclear export induced by CDKN2A. Hence, may regulate p53/TP53 expression and mediate in part the CDKN2A anti-proliferative activity. May also bind with ZNF385A the CCNB1 mRNA (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0000375 RNA splicing, via transesterification reactions GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile GO:0000398 mRNA splicing, via spliceosome GO:0006397 mRNA processing GO:0006417 regulation of translation GO:0008380 RNA splicing GO:0010608 posttranscriptional regulation of gene expression GO:0016441 posttranscriptional gene silencing GO:0016458 gene silencing GO:0017148 negative regulation of translation GO:0019827 stem cell population maintenance GO:0031047 gene silencing by RNA GO:0034248 regulation of cellular amide metabolic process GO:0034249 negative regulation of cellular amide metabolic process GO:0034250 positive regulation of cellular amide metabolic process GO:0035194 posttranscriptional gene silencing by RNA GO:0035195 gene silencing by miRNA GO:0040029 regulation of gene expression, epigenetic GO:0043487 regulation of RNA stability GO:0043488 regulation of mRNA stability GO:0043489 RNA stabilization GO:0045727 positive regulation of translation GO:0048255 mRNA stabilization GO:0060147 regulation of posttranscriptional gene silencing GO:0060149 negative regulation of posttranscriptional gene silencing GO:0060964 regulation of gene silencing by miRNA GO:0060965 negative regulation of gene silencing by miRNA GO:0060966 regulation of gene silencing by RNA GO:0060967 negative regulation of gene silencing by RNA GO:0060968 regulation of gene silencing GO:0060969 negative regulation of gene silencing GO:0070935 3'-UTR-mediated mRNA stabilization GO:0098727 maintenance of cell number GO:2000036 regulation of stem cell population maintenance
Molecular Function	GO:0003725 double-stranded RNA binding GO:0003729 mRNA binding GO:0003730 mRNA 3'-UTR binding GO:0017091 AU-rich element binding GO:0035925 mRNA 3'-UTR AU-rich region binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04152 AMPK signaling pathway
Reactome	R-HSA-74160: Gene Expression R-HSA-450520: HuR (ELAVL1) binds and stabilizes mRNA R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA R-HSA-450531: Regulation of mRNA stability by proteins that bind AU-rich elements R-HSA-72172: mRNA Splicing R-HSA-72163: mRNA Splicing - Major Pathway

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ELAVL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ELAVL1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23861541	Nasopharyngeal Carcinoma	Inhibit immunity	We showed that immunosuppressive prostaglandin E? (PGE?) led to the production and activity of the transcription factor CCAAT/enhancer binding protein δ (C/EBPδ) by stimulating the nucleocytoplasmic shuttling of the RNA binding protein Hu antigen R (HuR), which bound to and stabilized CEBPD mRNA in macrophages. Immunohistochemical analysis demonstrated that the amount of cytosolic HuR protein correlated with increased C/EBPδ abundance in TAMs in malignant nasopharyngeal carcinoma.

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ELAVL1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.56	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	STARS Score: 3.96; FDR: 0.033	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ELAVL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.106	0.535
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.061	0.974
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.141	0.92
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.185	0.684
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.336	0.859
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.851	0.739
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.01	0.979
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.163	0.928
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.174	0.93
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.054	0.971
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.505	0.815
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.094	0.0569

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ELAVL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ELAVL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ELAVL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ELAVL1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ELAVL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ELAVL1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ELAVL1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ELAVL1
Name	ELAV like RNA binding protein 1
Aliases	HuR; Hua; MelG; embryonic lethal, abnormal vision, drosophila, homolog-like 1; Hu antigen R; ELAV (embryonic ......
Chromosomal Location	19p13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ELAVL1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ELAVL1